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ABSTRACT Heat shock protein 90 (Hsp90) is a conserved molecular chaperone re-
sponsible for the folding and maturation of nascent proteins. Hsp90 is regarded as a
master regulator of protein homeostasis in the cell, and its inhibition affects the
functions of a large array of client proteins. The classical Hsp90 inhibitor tanespimy-
cin has shown potent antileishmanial activity. Despite the increasing importance of
Hsp90 inhibition in the development of antileishmanial agents, the global effects of
these inhibitors on the parasite proteome remain unknown. By combining tanespi-
mycin treatment with bioorthogonal noncanonical amino acid tagging (BONCAT)
metabolic labeling and isobaric tags for relative and absolute quantitation (iTRAQ)-
based quantitative proteomic mass spectrometry, for the first time, we robustly pro-
filed the relative changes in the synthesis of hundreds of parasite proteins as functions
of dose and duration of the inhibitor treatment. We showed that Hsp90 inhibition
dynamically regulates nascent protein synthesis in Leishmania mexicana, with many
chaperones and virulence factors showing inhibitor concentration- and treatment dura-
tion-dependent changes in relative expression. Many ribosomal proteins showed a
downregulation upon severe Hsp90 inhibition, providing the first protein-level evidence
that Hsp90 inhibition affects the protein synthesis capacity of the ribosome in this orga-
nism. We also provide an unbiased target validation of tanespimycin in L. mexicana using
live parasite photoaffinity labeling with a novel chemical probe and quantitative proteo-
mic mass spectrometry. We showed that the classical Hsp90 inhibitor not only engages
with its presumed target, Hsp83-1, in L. mexicana promastigotes but also affects multiple
proteins involved in protein synthesis and quality control in the parasite. This study
defines the Leishmania parasites’ response to Hsp90 inhibition at the level of nascent
global protein synthesis and provides a rich resource for future studies on Leishmania
spp. biology and antileishmanial drug development.
IMPORTANCE Leishmania spp. are the causative agents of leishmaniasis, a poverty-related
disease, which is endemic in .90 countries worldwide, affecting approximately 12 million
people, with an estimated 700,000 to 1 million new cases and around 70,000 deaths
annually. Inhibitors of the chaperone protein Hsp90 have shown promising antileishmanial
activity. However, further development of the Hsp90 inhibitors as antileishmanials is ham-
pered by a lack of direct information of their downstream effects on the parasite pro-
teome. Using a combination of mass spectrometry-based quantitative proteomics and
chemical and metabolic labeling, we provide the first protein-level evidence that Hsp90
inhibition affects global protein synthesis in Leishmania. We also provide the precise rela-
tive quantitative changes in the expressions of hundreds of affected proteins as functions
of both the concentration and duration of the inhibitor treatment. We find that
Leishmania regulates its ribosomal proteins under Hsp90 inhibition while a set of virulence
factors and chaperones are preferentially synthesized.
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Conserved from bacteria to mammals, heat shock protein 90 (Hsp90) acts as a mas-ter regulator of protein homeostasis in the cell by facilitating the maturation and
activation of a large array of client proteins involved in cell signaling, proliferation, and
survival (1). Hsp90 is a therapeutic target of significant interest for the treatment of
cancers (2) as well as several parasitic diseases, including leishmaniasis (3), Chagas dis-
ease (4), and malaria (5). The protozoan parasite Leishmania sp., the causative agent of
leishmaniasis, has been found to be critically reliant on Hsp90 for its stress adaptation
and survival during its complex digenetic life cycle (3, 6, 7). However, the biological
functions of Hsp90 in Leishmania, and the proteins it regulates in the parasite, remain
largely unknown.
Unlike in higher eukaryotes, the genomes of unicellular Leishmania spp. contain no
confirmed genes for transcriptional regulation or cis-acting regulatory DNA sequences
such as gene promoters and enhancers. The genes in Leishmania are organized into
long polycistronic transcription units that encode functionally unrelated proteins (8).
From the polycistronic transcripts, individual mature mRNAs are generated by 59 trans-
splicing of a small capped spliced leader sequence and 39 polyadenylation (9). In the
absence of promoter-mediated gene regulation, Leishmania spp. rely on posttranscrip-
tional mechanisms such as mRNA stability, protein translation, protein folding, degra-
dation, and posttranslational modifications (PTMs) for regulating gene expression (10).
As an essential protein, Hsp90 null mutants are not viable; therefore, reverse
genetic methods are not suitable for unravelling the functions of this important pro-
tein (7, 11). Therefore, a chemical inhibition approach would be ideal for systematically
analyzing the consequences of disrupting Hsp90 at the proteome level in the
Leishmania sp. parasite. The macrocyclic benzoquinone antibiotic tanespimycin, also
known as 17-allylamino-17-demethoxygeldanamycin (17-AAG), is the most studied in-
hibitor of Hsp90 (12). Tanespimycin was previously shown to potently inhibit the
growth of Leishmania spp. parasites both in vitro and in vivo (3). As Hsp90 regulates
many proteins, we sought for a direct protein-level characterization of the downstream
effects of Hsp90 inhibition on protein synthesis in the Leishmania parasite.
Deep sequencing of ribosome-protected mRNA fragments, termed ribosome profil-
ing, is emerging as a powerful method for analyzing protein translation (13). A recent
study employed ribosome profiling to monitor the effects of Hsp90 inhibition on
protein synthesis in Leishmania donovani parasites (14). In ribosome profiling, the asso-
ciation of mRNAs with translating ribosome is used as an indirect means to estimate
protein translation. A fundamental assumption in ribosome profiling is the uniformity
of translation elongation rates among all mRNAs in the cell (13). Although this is gener-
ally true, up to 20-fold variation in translation elongation rates among the open read-
ing frames (ORFs) has been reported (15). The differences in the translation elongation
rates between mRNAs is attributed to various factors, including codon biases, availabil-
ity of tRNAs, translational cofolding of polypeptides, and presence of positively
charged amino acids in the nascent polypeptide sequence (15–19). Translation elonga-
tion of mRNAs encoding ribosomal proteins (RPs) was reported to occur at a lower rate
that for other mRNAs with similar ribosome densities (15). Ribosome profiling also suf-
fers from many technical limitations. These include contaminating footprint-sized frag-
ments of rRNAs causing erroneous readouts of protein translation (20) and artifacts
caused by translation elongation inhibitors, as they alter the local distributions of ribo-
somes on an mRNA (21). Additionally, ribosome profiling requires a large input sample
(22), as at any given time point, only a fraction of mRNAs are associated with the ribo-
somes. In principle, every experimental step in ribosome profiling has the potential to
generate erroneous data output (23). Proteins compared to mRNAs are more robust for
sample handling, and quantitative proteomic mass spectrometry (MS)-based methods pro-
vide a more direct and more reliable alternative for measuring protein translation (24–29). A
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direct measurement of the nascent proteins is particularly important under stress conditions,
as recent studies indicate a poor correlation between indirect measurements of protein
synthesis from ribosome profiling and direct measurements using quantitative proteomic
MS (29). In the present study, using quantitative proteomic MS, we show that Hsp90 inhibi-
tion causes a global repression in protein synthesis in Leishmania mexicana. Importantly,
ribosome profiling is prone to bias when assessing translation under conditions of global
repression (30, 31).
We coupled tanespimycin treatment with bioorthogonal noncanonical amino acid
tagging (BONCAT) metabolic labeling (25) and isobaric tags for relative and absolute
quantitation (iTRAQ) (32) quantitative proteomic MS. Our results robustly identified, for
the first time, the dose- and time-dependent effects of tanespimycin treatment on the
synthesis of several key parasite proteins beyond its main target, Hsp90 (known as
Hsp83-1 in L. mexicana), pointing to a polypharmacology-based mechanism of action
for the compound. We find that L. mexicana responds to Hsp90 inhibition by selec-
tively downregulating its ribosomal protein synthesis while a preferential synthesis of
several virulence factors and chaperones occurs. The study defines the downstream
effectors of Hsp90 inhibition in L. mexicana and provides precise relative quantitation
of the effect of dose- and time-depended Hsp90 inhibition on hundreds of nascent
parasite proteins. Additionally, we evaluated for the first time the target engagement
of tanespimycin in L. mexicana using competitive affinity-based protein profiling
(AfBPP) (33–35) with a novel minimalist terminal alkyne photoaffinity probe that
closely mimics tanespimycin and revealed the protein target spectrum of the Hsp90 in-
hibitor in the parasite.
RESULTS
Quantitative proteomic MS profiling of tanespimycin-induced changes in
global nascent protein synthesis in L. mexicana. We employed a combination of
BONCAT and iTRAQ labeling-based quantitative proteomic MS (36) for a direct mea-
surement of effect of tanespimycin treatment on protein synthesis in L. mexicana pro-
mastigotes (Fig. 1). We treated the parasites with three different concentrations (2mM,
10mM, and 25mM) of tanespimycin and vehicle (dimethyl sulfoxide [DMSO]) in three
replicates for 2 h in a methionine-free Schneider’s medium supplemented with azido-
homoalanine (AHA). The short treatment window and the tanespimycin concentration
range were chosen to robustly profile differentially expressed proteins in the early peri-
ods of Hsp90 inhibition without causing an impact on parasite viability. Following the
treatments, the parasites were lysed, and the whole-cell lysates were subjected to a
click reaction (37) with a biotin-alkyne capture reagent and affinity enriched on
NeutrAvidin-agarose resin. After on-bead tryptic digestion, the samples were labeled
with iTRAQ 4-plex reagents and analyzed by liquid chromatography tandem mass
spectrometry (LC-MS/MS) (see Table S1 in the supplemental material). Only subtle
changes were observed in the nascent proteins from 2mM to 10mM concentration of
tanespimycin. However, a higher concentration (25mM) of the inhibitor caused a statis-
tically significant global decrease in nascent protein synthesis, revealing that Hsp90 in-
hibition significantly affects protein translation in this organism even during a short 2-
h treatment window (Fig. 2A). More importantly, the quantitative proteomic MS results,
as presented in the volcano plots (Fig. 2B, C and D), showed tanespimycin concentra-
tion-dependent altered expression of several newly synthesized proteins (NSPs).
Chaperone Hsp70, a major component of the Hsp90 foldosome complex, is consis-
tently identified among the top abundantly expressed NSPs upon tanespimycin treat-
ment. Hsp90 inhibition in human cancer cells was previously reported to cause unde-
sirable activation of the master heat shock transcription factor 1 (HSF1), which in turn
causes increased expression of the cytoprotective chaperones, mainly Hsp70, leading
to counterproductive cytoprotective heat shock responses during cancer therapy (38,
39). Our results indicate that similarly to that in human cancer cells, quantifiable
increased expression of Hsp70 is a hallmark of Hsp90 inhibition in L. mexicana. More
importantly, our study revealed, for the first time, that expression of not only Hsp70
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but also a panel of other parasite proteins increased upon inhibition of Hsp90. The
statistically significant differentially expressed proteins among these NSPs (represented
by red filled circles on the top right of each volcano plot in Fig. 2B, C, and D) are poten-
tial molecular mediators of the parasite’s adaptation to the Hsp90 inhibition stress. Our
results also showed that Hsp90 (Hsp83-1) is among the most increasingly expressed
NSPs upon its own inhibition in L. mexicana. The iTRAQ 4-plex labeling approach addi-
tionally enabled quantitative comparison of the relative changes in the expressions of
the NSPs as a function of the concentration of the Hsp90 inhibitor (Table S1). At the
lower 2mM tanespimycin treatment, the increased Hsp70 expression was more promi-
nent, while with increased tanespimycin, the Hsp70 expression relative to that of
Hsp83-1 was found to decrease (Fig. S1). The Hsp90 inhibitor concentration-dependent
relative changes in abundances were also visible in several other NSPs (Fig. S1).
Temporal effect of Hsp90 inhibition on global nascent protein synthesis in L.
mexicana. To assess the temporal effect of tanespimycin treatment on global protein
synthesis in L. mexicana, the compound treatment was combined with the BONCAT-
iTRAQ quantitative proteomic MS workflow using a fixed concentration of 50mM but
varying the treatment duration (1 h and 4 h) (Fig. 3A). The maximum treatment dura-
tion was limited to 4 h, as it was reported earlier as a suitable time window for avoiding
irreversible effects of tanespimycin on Leishmania (40). Despite its high potency, the
parasite-killing effect of tanespimycin take place slowly, and even 100mM tanespimy-
cin did not cause a significant effect on L. mexicana viability within the 4-h treatment
period (data not shown). Two separate iTRAQ duplex experiments were performed in
triplicates to take into account the temporal effects of protein synthesis in the tanespi-
mycin-untreated samples. A total of 158 and 200 NSPs were identified after filtering
away contaminants, endogenous biotinylated proteins, and proteins identified with
FIG 1 Schematic overview of the Hsp90 inhibition combined with BONCAT metabolic labeling and
iTRAQ-based quantitative proteomic MS for systematic profiling of effect of Hsp90 inhibition on
protein synthesis in Leishmania.
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less than 2 unique peptides for the 1-h and 4-h treatment windows, respectively (see
Tables S2 and S3). Of these Hsp90 inhibition-responsive NSPs, statistically significant
enrichment across the three replicates was identified for 156 and 73 proteins for the 1-
h and 4-h treatments, respectively. As shown in the violin plots (Fig. 3B), a dramatic
decrease in the global synthesis of new proteins was observed at the 4-h Hsp90 inhibi-
tion window compared to that for the 1-h treatment, revealing the temporal effect of
severe Hsp90 inhibition on protein translation in this organism. An increase in the syn-
thesis of many proteins with respect to the vehicle treatment was observed at the ini-
tial 1-h Hsp90 inhibitor treatment period (Fig. 3C). However, as the inhibition pro-
ceeded to 4 h, repression in the synthesis of many RPs was observed (Fig. 3D),
indicating that the Hsp90 inhibition affects the state of the ribosome in L. mexicana as
reported in the case of mammalian cells (41, 42).
Protein-protein interaction network analysis of the Hsp90 inhibition-affected nas-
cent proteins using STRING database (43) of a related Leishmania major species
showed known interactions within the network (see Fig. S2). Gene ontology (GO)
FIG 2 Characterization of effect of Hsp90 inhibition on nascent protein synthesis in L. mexicana promastigotes. (A) Violin plot demonstrating the
tanespimycin concentration-dependent dynamic changes in global nascent protein synthesis. Volcano plots show significant enrichment of newly
synthesized proteins at 2mM (B), 10mM (C), and 25mM (D) tanespimycin treatment over that with vehicle (DMSO) treatment across three replicates. A
modified t test with permutation-based FDR statistics was applied (250 permutations, FDR= 0.05) to compare tanespimycin-treated and vehicle-treated
groups.
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analysis of the statistically significant downregulated proteins revealed structural con-
stituent of ribosome (P value, 2.93e245) and translation (P value, 7.29e240) as extremely
enriched molecular function and biological process GO terms, respectively (see
Fig. S3A). Importantly, the quantitative proteomic MS approach enabled not only the
identification but also the quantitation of relative changes in the expression levels of
the affected RPs. Despite the repression in RP synthesis, increased expression of a
smaller set of L. mexicana proteins occurred under Hsp90 inhibition. The statistically
FIG 3 Temporal effect of Hsp90 inhibition on nascent protein synthesis in L. mexicana promastigotes. (A) Schematic of the workflow involving
tanespimycin treatment combined with BONCAT metabolic labeling and iTRAQ-quantitative proteomic MS. (B) Violin plot demonstrating the significant
decrease of global protein synthesis at 4 h compared to that at 1 h of treatment. Volcano plots show enrichment of newly synthesized proteins at 1 h (C)
and 4 h (D) of tanespimycin treatment (50mM) over that with vehicle (DMSO) treatment across three replicates. A modified t test with permutation-based
FDR statistics was applied (250 permutations, FDR= 0.05) to compare tanespimycin-treated and vehicle-treated groups.
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significant proteins (red filled circles at upper right portion of Fig. 3D) preferentially
synthesized by the parasite under severe Hsp90 inhibition include known virulence fac-
tors superoxide dismutase (SOD) (44), Hsp70 (45), and dipeptidyl peptidase 3 (46), im-
portant metabolic enzymes, and histone H4. Gene ontology (GO) analysis of the statis-
tically significant upregulated proteins revealed unfolded protein binding (P value,
3.77e26) and protein folding (P value, 2.53e27) as significantly enriched molecular func-
tion and biological process GO terms, respectively (Fig. S3B). Collectively, the nascent
proteins preferentially synthesized by L. mexicana under Hsp90 inhibition revealed in
this study are functionally important proteins that the parasite relies upon to mitigate
the cytotoxic effects of Hsp90 inhibition.
In situ photoaffinity labeling combined with quantitative proteomic MS revealed
targets of tanespimycin in L. mexicana. For an unbiased validation of tanespimycin
(Fig. 4A) target engagement in L. mexicana, we developed a quantitative chemical pro-
teomics workflow. We first synthesized a novel tanespimycin probe 17-minimalist
alkyne diazirine aminogeldanamycin (17-mADAG) (Fig. 4B) that closely mimics the
chemical structure of tanespimycin but is equipped with a terminal alkyne tag for click
chemistry and diazirine functionality (47) for photo-cross-linking of target proteins in
proximity. The 17-mADAG probe was utilized in a live parasite competitive photoaffin-
ity-based protein profiling (AfBPP) (33–35) coupled with iTRAQ quantitative proteomic
MS (Fig. 5A). Prior to performing the chemical proteomics target validation, we eval-
uated the antileishmanial activity of the probe in L. mexicana log-phase promastigotes
in comparison with that of tanespimycin. Both compounds exhibited potent and com-
parable activity, with 50% inhibition concentration (IC50) values of 211 nM and 640 nM
for tanespimycin and 17-mADAG, respectively, in antiproliferative assays (see Fig. S4).
Additionally, docking analyses, in agreement with a recent study (48), also revealed
similar binding poses for 17-mADAG and tanespimycin at the ATP-binding pocket of L.
mexicana Hsp83-1 (see Fig. S5), with both compounds exploiting similar binding inter-
actions and solvent-exposed sidechains on the position C-17.
Using equimolar concentrations of the probe and the competitor tanespimycin,
probe-only-treated parasites as well as probe- and tanespimycin-treated parasites in
three replicates were subjected to UV irradiation. Following cell lysis, the extracts were
clicked with a biotin-azide, and the labeled proteins were affinity enriched on
NeutrAvidin-agarose resin. After on-bead tryptic digestion, the samples were subjected
to iTRAQ duplex labeling and analyzed by LC-MS/MS. A total of 16 target proteins
(Fig. 5B; see also Table S4) were retained after filtering away proteins identified with
fewer than 2 unique peptides, contaminants, and endogenous biotinylated proteins.
While Hsp83-1 (see Fig. 5C for a representative LC-MS/MS spectrum of a tryptic pep-
tide) pulled out by the probe revealed its on-target engagement, the enrichment of
other proteins shows, for the first time, that Hsp90 inhibition targets multiple proteins
in the Leishmania parasite.
FIG 4 Chemical structures of tanespimycin (A) and 17-mADAG (B).
Characterizing Hsp90 Inhibition in Leishmania mexicana
May/June 2021 Volume 6 Issue 3 e00089-21 msystems.asm.org 7
 on M









Differential quantitative proteomic profiling of the direct effect of Hsp90 inhibition
on the L. mexicana promastigote proteome. For additional characterization of the direct
effect of Hsp90 inhibition on the L. mexicana promastigote proteome, we performed differ-
ential quantitative proteomic profiling using label-free quantification (LFQ) proteomic MS
(49) of the inhibitor versus vehicle treatment conditions. The lysates after in-solution tryptic
digestion and LC-MS/MS were analyzed by MaxLFQ (50). As in the case of the nascent pro-
teins, the Hsp90 inhibitor affected the expression levels of hundreds of L. mexicana proteins
(Fig. 6; see also Table S5). Similarly, in agreement with the NSP profiling, Hsp90 and several
other chaperon proteins remained among the most significantly elevated proteins.
DISCUSSION
Leishmania spp. parasites are among the most ancient lineages in the evolution of
eukaryotes and possess a peculiar genomic organization with a notable absence of
introns. The proteome and the transcriptome are poorly correlated in this organism
(51). Quantitative proteomic MS that provides a direct measurement of the proteome
is therefore particularly suitable for the measurement of translation in Leishmania spp.
Here, we report the first systematic study of the effect of Hsp90 inhibition on global
protein synthesis in L. mexicana parasites using BONCAT metabolic labeling and
FIG 5 (A) Schematic of the competitive AfBPP using the probe (17-mADAG) and the competitor (tanespimycin) combined with iTRAQ duplex labeling-
based quantitative proteomic MS in L. mexicana promastigotes. (B) Protein targets of 17-mADAG identified across three replicate AfBPP-iTRAQ-LC-MS/MS
experiments presented in a bar chart. The fold change (FC) in abundance of the enriched proteins in the 17-mADAG-treated samples relative to that in the
17-mADAG plus the competitor (tanespimycin)-treated samples in log2 scale times the observed MaxQuant search score of each identified protein is
shown. (C) A representative MS/MS spectrum of a tryptic peptide of L. mexicana Hsp83-1 identified by database search using MaxQuant showing the
observed y and b ion fragmentation patterns.
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quantitative proteomic MS. This robust methodology enabled highly sensitive profiling
of relative changes in the synthesis of hundreds of L. mexicana proteins as functions of
the dose and duration of the Hsp90 inhibitor treatment. As a master regulator of pro-
tein homeostasis, it is conceivable that the inhibition of Hsp90 will have major conse-
quences on the stabilization, activation, and degradation of many cellular proteins. In
mammalian cells, molecular chaperones play dual roles of facilitating polypeptide elon-
gation and cotranslational folding at the ribosome (41), and Hsp90 inhibition affects
the protein synthesis capacity of the ribosome (42).
Our results provide the first protein-level evidence that severe Hsp90 inhibition in
Leishmania spp. causes a decrease in the synthesis of many RPs, while the synthesis of
many virulence factors and quality control proteins remains upregulated. Although RPs
act as integral structural constituents of the ribosome, many of them are known to
have extraribosomal functions. For instance, in prokaryotes, RPL4 is known to inhibit
translation of polycistronic mRNAs (52). The eukaryotic RPS3, a component of the 40S
ribosomal small subunit, acts as a DNA repair endonuclease (53). It also regulates cell
growth and apoptosis in some cell lines (54). In human cell lines, Hsp90 directly inter-
acts with RPS3, and this interaction has been reported to protect the RP from ubiquiti-
nation and subsequent proteasome-dependent degradation, thereby retaining the
function and biosynthesis of the ribosome (42). In eukaryotes, many RPs regulate the
synthesis of the protein and RNA components of the ribosome itself (55). RPs S13, S14,
L12, and L30 can inhibit their own mRNA splicing (56–59). Similarly, RPs S28 and L2 are
known to shorten their own mRNA half-lives (60, 61). In Drosophila, RPL22 associates
with the liker histone H1 and causes repression of several genes (62). In yeast, RP L6 posi-
tively modulates RNA polymerase III transcription (63). In L. donovani, 60S ribosomal L23a
has been found to be overexpressed in different sodium antimony gluconate-resistant
strains and play crucial roles in parasite survival and proliferation (64). The cytosolic ribosome
was recently identified as the primary drug target of the aminoglycoside antileishmanial
drug paromomycin (65). The statistically significant preferential downregulation of many RPs
upon treatment with the Hsp90 inhibitor revealed in our study indicate that the major
downstream effect of the inhibitor in L. mexicana is on the parasite ribosome.
SOD, an increasingly expressed protein upon Hsp90 inhibition, is an important compo-
nent of Leishmania’s antioxidant system and is a known virulence factor (44). The dismutation
FIG 6 Volcano plot showing the enrichment of L. mexicana promastigote proteins upon Hsp90
inhibition with tanespimycin treatment (1mM for 12 h) over that with vehicle (DMSO) treatment
across three replicates profiled by label-free quantification (LFQ) proteomic MS. A modified t test
with permutation-based FDR statistics was applied (250 permutations, FDR = 0.05) to compare
tanespimycin-treated and vehicle-treated groups.
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reaction catalyzed by SOD generates hydrogen peroxide within mitochondria. This has been
shown to play a crucial role in the differentiation of Leishmania amazonensis promastigotes
to infective amastigotes (44). Prolonged treatment with Hsp90 inhibitors also induces promas-
tigote-to-amastigote differentiation in Leishmania spp. (6). However, the downstreammolecu-
lar mechanisms of this differentiation process remain unknown. It is likely that the increased
expression of SOD partly contributes to the Hsp90 inhibition-mediated differentiation in
Leishmania spp. Among the other preferentially synthesized proteins, malate dehydrogenase,
an important enzyme in the tricarboxylic acid cycle, was previously identified as a trigger for
polyclonal B-cell activation during the acute phase of Trypanosoma cruzi infection, facilitating
the infection in vivo (66). Similarly, sucrose-phosphate synthase-like protein, an enzyme
involved in sugar metabolism, was previously identified among proteins that are highly
expressed in a virulent strain of L. major but not in an avirulent strain of the same species
(67). The increased synthesis of histone H4, which is in agreement with a recent ribosome
profiling study in L. donovani (14), indicates the possibility of chromatin reorganization in
Leishmania under cellular stress caused by Hsp90 inhibition (68, 69). The preferentially upreg-
ulated proteins identified in this study, many of which are identified or presumed virulence
factors, represent a set of target proteins for systematic development of drug combination
studies with the Hsp90 inhibitor treatment. Our results thus provide a rich resource for further
studies on the prospects of Hsp90 inhibition in the Leishmania parasite.
We also report a systematic chemical proteomics target validation of tanespimycin
in L. mexicana. The combination of competitive activity/affinity-based protein profiling
(ABPP/AfBPP) with quantitative proteomic MS has evolved as a powerful unbiased
method for target and off-target profiling of biologically active agents (33–35). Our
chemical proteomics target profiling using the novel tanespimycin analogue, the mini-
malist terminal alkyne diazirine compound 17-mADAG, revealed that the classical
Hsp90 inhibitor not only engages with its presumed target Hsp90 in L. mexicana but
also affects multiple proteins involved in protein synthesis and quality control. Hsp90
directly associates with many clients and forms multiprotein complexes (1). Therefore,
it is possible that some of the identified off-targets were pulled down due to their close
physical association with the main target Hsp90, as the photo-cross-linking is proximity
driven (70). The identification of translation elongation factors and RPs in the chemical
proteomics experiment provides additional validation for the BONCAT-iTRAQ quantita-
tive proteomic MS findings that Hsp90 inhibition affects protein translation and RP syn-
thesis in L. mexicana.
MATERIALS ANDMETHODS
Leishmania cell culture. L. mexicana strain M379 (MNYC/BC/62/M379) promastigotes were grown in
T-25 flasks at 26°C in Schneider’s insect medium (Sigma-Aldrich) supplemented with 0.4 g/liter NaHCO3,
0.6 g/liter anhydrous CaCl2, and 10% fetal bovine serum (FBS) (pH 7.2).
Growth inhibition assay. Growth inhibition assays were performed as previously described (71).
Briefly, serial 3-fold dilutions of the two compounds (tanespimycin and 17-mADAG) in triplicates in the
growth medium (Schneider’s insect medium, pH 7.2 supplemented with 0.4 g/liter NaHCO3, 0.6 g/liter
anhydrous CaCl2, and 10% FBS) starting with a 50mM concentration were performed in flat-bottom 96-
well cell culture microtiter plates. Amphotericin B was used as positive control, and DMSO was used as
negative control. L. mexicana promastigotes were plated at a concentration of 106 parasites/ml. After
48 h of incubation, the parasite viability was determined by alamarBlue assay (20 ml/well freshly pre-
pared 0.15mg/ml resazurin in phosphate-buffered saline [PBS]), reading the fluorescence emission at
590 nm (bandwidth, 10 nm) following excitation at 550 nm (bandwidth, 10 nm) using a BioTek SYNERGY
HTX microplate reader.
In situ photoaffinity labeling. L. mexicana promastigotes grown to mid-log phase (;5 106 para-
sites/ml) in Schneider’s insect medium supplemented with 10% FBS were plated in 24-well plates with
500 ml medium per well. 17-mADAG was added to the culture medium with or without equimolar
amounts of tanespimycin for different durations (4 h to 16 h), after which, the medium was replaced
with PBS and the parasites were irradiated with UV light (6-W lamp, ;365-nm wavelength) for 10 min
on ice. The parasites with or without UV-irradiation were collected by centrifugation at 1,000  g for 3
min, washed with PBS, and immediately lysed using a lysis buffer (50mM HEPES, pH 7.4, 150mM NaCl,
4% SDS, 250 U Benzonase). Protein concentrations of the lysates were determined using a Bio-Rad DC
protein assay, and lysates at a 1-mg/ml concentration were subjected to click chemistry with biotin-az-
ide. Following the click reactions, proteins were precipitated using a methanol-chloroform-water mix-
ture (4:1:3), washed, resolubilized in a buffer with 4% SDS, diluted to 0.1% SDS, and subjected to affinity
enrichment on NeutrAvidin-agarose resin.
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Tanespimycin treatment and metabolic labeling of nascent proteins. L. mexicana promastigotes
grown to mid-log phase (;5 106 parasites/ml) in Schneider’s insect medium were placed in methio-
nine-free Schneider’s medium supplemented with 10% dialyzed FBS and 50mM azidohomoalanine
(AHA). For profiling the effects of tanespimycin treatment on the nascent protein synthesis by iTRAQ 4-
plex labeling, the parasites in three replicates were treated with three different concentrations (2, 10,
and 25mM) of the Hsp90 inhibitor for 2 h. DMSO instead of tanespimycin was used as a vehicle control.
For profiling the temporal effects of tanespimycin treatment by iTRAQ duplex experiments, a fixed
50mM concentration of tanespimycin was used in three replicates for 1-h and 4-h durations along with
equal durations of vehicle (DMSO) treatments. Following treatments, the parasites were lysed using lysis
buffer (50mM HEPES, pH 7.4, 150mM NaCl, 4% SDS, 250 U Benzonase), and the protein concentrations
were determined using a Bio-Rad DC protein assay.
Click chemistry and affinity enrichment.Whole-cell extracts of the Leishmania parasites at a 1-mg/
ml concentration were treated with freshly premixed click chemistry reaction cocktail (100mM capture
reagent [biotin-azide for 17-mADAG treatment or biotin-alkyne for the nascent protein profiling; 10mM
stock solutions in DMSO], 1mM CuSO4 solution [50mM stock solution in Milli-Q water], 1mM tris[2-car-
boxyethyl]phosphine solution [TCEP solution; 50mM stock solution in Milli-Q water], and 100mM tris[{1-
benzyl-4-triazolyl}methyl]amine solution [TBTA solution; 10mM stock solution in DMSO]) for 3 h at room
temperature. Proteins were precipitated by adding methanol (4 volumes), chloroform (1.5 volumes), and
water (3 volumes) and collected by centrifugation at 14,000  g for 5 min. The protein precipitates were
washed twice with methanol (10 volumes; centrifugation at 14,000  g for 5 min to collect the pellets),
and the supernatants were discarded. The protein pellets were air dried at room temperature for 20 min
and stored in a 280°C freezer.
For affinity enrichment, the air-dried protein pellets obtained after the click reactions and protein
precipitation were dissolved in phosphate-buffered saline (PBS) with 2% SDS to a 5-mg/ml concentra-
tion by sonication. In a typical affinity enrichment experiment, 300mg of the parasite lysate subjected to
click reaction and protein precipitation was resuspended in 50 ml 2% SDS in PBS. The samples were then
diluted 20-fold with PBS so that the final SDS amount was 0.1%. The samples were centrifuged at
10,000  g for 5 min to remove insoluble debris, and the clear soluble portion was used for the affin-
ity enrichment. Typically, 30 ml of NeutrAvidin-agarose beads, freshly washed three times with 0.1%
SDS buffer (0.1% SDS in PBS), was added to each of the samples, and the mixtures were rotated on an
end-over-end rotating shaker for 1.5 h at room temperature. The beads were then washed 3 times
with 1% SDS in PBS, 3 times with 6 M urea in PBS, 3 times with PBS, and once with 25mM triethylam-
monium bicarbonate (TEAB) buffer. Each washing was performed with 20 volumes of the washing
solutions with respect to the bead volume, and centrifugation of the beads between washing steps
was carried out at 2,000  g for 1 min at room temperature.
On-bead reduction, alkylation, and tryptic digestion. Thoroughly washed beads from the affinity
enrichment step were resuspended in 150ml of 25mM TEAB buffer and treated with 10mM TCEP
(200mM stock solution in water) for 45 min at 35°C. The beads were washed once with 25mM TEAB
buffer, resuspended in 150ml of 25mM TEAB buffer, and treated with 15mM chloroacetamide (CAA;
200mM stock solution in water) in the dark for 20 min at room temperature. The beads were again
washed with 25mM TEAB buffer, resuspended in 200ml of fresh 50mM TEAB buffer, and treated with
5mg of sequencing-grade modified trypsin at 37°C for 16 h. The samples were centrifuged at 5,000  g
for 5 min at room temperature to collect the supernatant. The beads were washed twice with 50% (vol/
vol) acetonitrile (ACN) containing 0.1% (vol/vol) formic acid (FA; 50 ml for each wash) and mixed with
the previous supernatant. The collected tryptic peptides were acidified to pH 3 using FA and evaporated
to dryness. The peptides were then redissolved in 0.1% (vol/vol) FA solution in water and subjected to
desalting on Pierce C18 spin columns (Thermo Scientific; catalog number 89873) according to the manu-
facturer’s instructions. The peptides were evaporated to complete dryness under a vacuum.
iTRAQ labeling. The iTRAQ labeling reactions were carried out as previously described (36). Briefly,
the dried peptides were resuspended in equal volumes (30 ml) of dissolution buffer (0.5 M TEAB buffer
supplied with the iTRAQ reagents multiplex kit). Two hundred ten microliters of absolute ethanol was
added to each iTRAQ reagent vial preequilibrated to room temperature. The contents of each iTRAQ rea-
gent vial were split into 3 equal portions (70ml each), and each portion was quickly transferred to the re-
spective vials of desalted and dried peptide digests. The labeling reactions were performed for 1.5 h at
25°C and quenched with 100mM Tris base solution (1 M stock solution). The samples labeled with the
different iTRAQ channels from the same experiments were pooled into a fresh vial and concentrated on
a speed-vac. The dried peptides were reconstituted in water with 0.1% (vol/vol) FA and 2% (vol/vol) ACN
and subjected to desalting on C-18 Sep-Pak Classic cartridges (Waters; WAT051910) following manufac-
turer’s instructions. The eluted peptides were concentrated on a speed-vac and subjected to a second
round of cleaning up on HILIC TopTip (PolyLC; TT200HIL) solid-phase extraction tips following manufac-
turer’s instructions. The eluted peptides were concentrated on a SpeedVac and reconstituted in aqueous
0.1% (vol/vol) FA.
Tanespimycin treatment and in-solution tryptic digestion. L. mexicana promastigotes grown to
mid-log phase (;5 106 parasites/ml) in hemoflagellate-modified minimum essential medium
(HOMEM) supplemented with 10% FBS were treated in three replicates with tanespimycin (1mM) or
DMSO for 12 h. Following treatments, the parasites were lysed using lysis buffer (20mM Tris-HCl, pH 8.5,
8 M urea, 1mM dithiothreitol [DTT], Roche cOmplete EDTA-free protease inhibitor cocktail), passed
through a 29-gauge needle, and centrifuged at 4°C for 5min at 5,000  g, and the protein concentra-
tions in the clear lysates were determined. Three hundred micrograms of each lysate was subjected to
in-solution tryptic digestion using 6mg of sequencing-grade modified trypsin at 37°C for 16 h after
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reduction with 5mM DTT and S-carbamidomethylation with 10mM iodoacetamide. The samples were
acidified to pH 3 using FA, desalted on C18 Sep-Pak Classic cartridges, concentrated on a SpeedVac, and
reconstituted in aqueous 0.1% (vol/vol) FA.
LC-MS/MS analysis. The iTRAQ-labeled peptides and in-solution tryptic digests were resolved on an
ekspert nanoLC 425 with a low microgradient flow module (Eksigent) using a YMC-Triart C18 column
(12 nm, S-3mm, 150 mm by 0.3mm inside diameter [i.d.], 1/32 in.; part number TA12S03-15H0RU). A C18
trap column (Trap-YMC-Triart 12 nm S-5mm, 5 mm by 0.5-mm i.d., 1/32 in.; part number: TA12S05-
E5J0RU) was connected prior to the main separating column. Five microliters of iTRAQ-labeled peptides
was separated by mobile phase A (0.1% FA in water) and mobile phase B (0.1% FA in ACN) at a flow rate
of 5 ml/min over 87min. The gradient used was the following: 3% B to 5% B (0 to 2min), 5% B to 30% B
(2 to 68min), 30% B to 35% B (68 to 73min), 35% B to 80% B (73 to 75min), 80% B (75 to 78min), 80% B
to 3% B (78 to 79min), and 3% B (79 to 87min). For the in-solution tryptic digests, a 90-min total gradi-
ent with 2-min postrun equilibration in ending buffer was performed. Five microliters of sample pep-
tides was separated by mobile phase A and mobile phase B. The gradient used for the in-solution tryptic
digests was the following: 3% B to 30% B (0 to 60 min), 30% B to 40% B (60 to 77 min), 40% B to 80% B
(77 to 79 min), 80% B (79 to 82 min), 80% B to 3% B (82 to 84 min), and 3% B (84 to 90 min). The MS anal-
yses were performed on a TripleTOF 6600 system (Sciex) in high-resolution mode. The MS acquisition
time was set from gradient time zero to 85min, and the MS1 spectra were collected in the mass range
of 400 to 1,500 m/z with 250-ms accumulation time per spectrum. Further fragmentation of each MS1
spectrum occurred with a maximum of 30 precursors per cycle and 33-ms minimum accumulation time
for each precursor across the range of 100 to 1,500 m/z with ion selection 12 to 15, 500 cps intensity
threshold and dynamic exclusion for 15 s. The MS/MS spectra were acquired in high-sensitivity mode.
Proteomics MS data processing. For protein identification and quantification, the .wiff files from
the Sciex TripleTOF 6600 system were imported into MaxQuant (version 1.6.3.4) (72) with integrated
Andromeda database search engine (73). The MS/MS spectra were queried against L. mexicana sequen-
ces from UniProt KB (8,524 sequences). The database search employed the following parameters: re-
porter ion MS2 with multiplicity 4plex for the iTRAQ 4-plex experiments and multiplicity 2plex for the
iTRAQ duplex experiments, trypsin digestion with maximum 2 missed cleavages, carbamidomethylation
of cysteine as fixed modification, oxidation of methionine and acetylation of protein N termini as vari-
able modifications, maximum number of modifications per peptide set at 5, minimum peptide length of
6, and protein false discovery rate (FDR) of 0.01. Appropriate correction factors for the individual iTRAQ
channels for both peptide N-terminal labeling and lysine side chain labeling as per the iTRAQ reagent
multiplex kit were also configured into the database search. Label-free quantification in MaxQuant was
performed using the built-in MaxLFQ algorithm. The type of LC-MS run was set as standard with multi-
plicity 1 for the LFQ experiments. Tanespimycin treatments and DMSO treatments were set as two sepa-
rate parameter groups, and the MaxLFQ algorithm was applied independently to the two different pa-
rameter groups. The proteinGroups.txt file from the MaxQuant search output was processed using
Perseus software (version 1.6.2.3) (74). Potential contaminants, reverse sequences, sequences only identi-
fied by site, and endogenous biotinylated proteins were filtered out. Additionally, proteins with fewer
than 2 unique peptides identified were discarded. For each identified protein, the ratios of the tanespi-
mycin treated and AHA-labeled reporter intensity corrected values to the vehicle treated and AHA-la-
beled reporter intensity corrected values or the ratios of the probe treated to probe and tanespimycin
treated reporter intensity corrected values from the corresponding experiment were calculated yielding
the fold change (FC). The FCs obtained for each protein were transformed into log2 scale, and volcano
plots were generated following a t test on the three replicates, with significant data points determined
with a permutation-based FDR calculation (FDR= 0.05, number of randomizations = 250).
Gene ontology analysis. The gene ontology terms (biological process and molecular function) sig-
nificantly enriched in the nascent proteins synthesized under Hsp90 inhibition in L. mexicana promasti-
gotes relative to the predicted whole proteome of the organism were derived using TriTrypDB (75).
REVIGO software (76) was used to refine and visualize the enriched gene ontology terms.
Protein-protein interaction network analysis. Network analysis of the Hsp90 inhibitor-affected L.
mexicana nascent proteome was performed by using the publicly available STRING database (version
11.0) of L. major strain Friedlin. The open source software platform Cytoscape (version 3.8.2) (77) was
used for refining and visualizing the protein interaction network. Upregulated and downregulated pro-
teins were presented as green and yellow nodes, respectively, and the STRING database score of each
interaction was embedded in the width of the network edges.
Homology modeling and docking. The N-terminal domain of Hsp90 protein from L. major (PDB
identifier [ID] 3Q5L) was used as a template to build the homology model of Hsp83-1 protein of L. mexi-
cana. Both proteins share 96% sequence similarity. The fully automated homology modeling server
Swiss-Model (78) was used to construct the model with default settings. The “protein preparation wiz-
ard” (79) implemented in Maestro 11.9 graphical user interface of the Schrodinger software suite (release
2019-1) was used to prepare the protein model. The bond type and bond orders were corrected. The
hydrogen atoms were reassigned after deleting the original ones. The protonation states of acidic/basic
amino acids were adjusted for pH 7.0. The OPLS2003e forcefield (80–82) was used for the restrained min-
imization of the protein with the convergence criterion of root mean square deviation (RMSD) of 0.3 Å
for the heavy atoms. Ligands were sketched within Maestro and prepared using the LigPrep program of
the Schrodinger software suite. The Epik 4.7 program (83, 84) was used to generate energetically accessi-
ble protonation states. The absolute stereochemistry of all the stereocenters was predefined, and no tau-
tomeric forms were generated for the ligands. Molecular docking of the prepared ligands (17-AAG and
GMD-probe) was performed using Autodock Vina (85, 86), implemented in the open source PyRx
Kalesh et al.
May/June 2021 Volume 6 Issue 3 e00089-21 msystems.asm.org 12
 on M









software (87) (version 0.8). The active-site residues were enclosed in a grid box cantered around the x, y,
and z coordinates of 262.421, 228.580, and 232.474, respectively. The dimensions of the grid box were
set to 25.43, 18.70, and 16.28Å to include all the active-site residues. The exhaustiveness was set to 8,
and all other default settings for Autodock Vina were used for the docking. The docked poses of ligands
with the highest predicted binding affinity were reported, and images were generated using Discovery
studio visualizer version 20.1.0 of Biovia Dassault Systèmes.
Data availability. All raw mass spectrometry proteomic data have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository with the data set identifiers PXD022708
and PXD024764.
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